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a b s t r a c t
The human genome contains a large number of endogenous retroviruses (HERVs). Their reactivation has
frequently been observed in patients with cancer. Considering their role in the carcinogenesis process,
we aimed to study the possible relationship between HERVs gene expression and Chronic Lymphocytic
Leukemia (CLL). We focused on two viral genes gag and np9, the latter presumably an oncogene. We
found that the transcriptional activity of HERV-K np9 gene was greater in CLL patients than in healthy
donors. However, gag expression was not signiﬁcantly increased.
These ﬁndings suggest a noteworthy relationship between CLL disease and HERV-K np9 expression.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Human endogenous retroviruses (HERVs) are genetic remnants of
ancient retroviral infections of the germ line produced during primate
evolutionwhich are now transmitted vertically. To date, approximately
8% of the human genome is composed of such retroviral sequences [1].
Most HERVs are dysfunctional due to numerous mutations and
deletions. However, those belonging to HERV-K family, contain
sequences which are likely to be transcribed.
Many of these HERVs are transcribed and translated under
normal physiological conditions. Nevertheless, reactivation of HERVs
has frequently been observed in a variety of human tumors suggest-
ing their potential to contribute to malignant progression [2].
Speciﬁcally during hemato-oncological processes, several studies
have reported the presence of antibodies against HERV-K, over-
expression of HERV genes and also the presence of retroviral particles
in primary leukemia cells [2]. In addition, np9, a small regulatory
gene encoded by HERV-K, has a role as a potent viral oncogene and
as a critical molecular switch of multiple signaling pathways regulat-
ing the growth of certain human myeloid and lymphoblastic leuke-
mia cells [3].
CLL is the most common form of leukemia in Western countries
and mainly affects elderly individuals. It follows an extremely
variable course, with survival ranging from months to decades.
Available treatments often induce disease remission, but almost all
patients will relapse and there is a consensus that CLL remains
incurable. To date, both an unmutated (UM) proﬁle of immuno-
globulin (Ig) VH genes as well as the presence of genetic lesions at
chromosome 17p13, or at 11q23 constitute poor prognosis indica-
tors [4]. Several studies have begun to shed light on the nature of
genetic predisposition of CLL but the basis of this disorder remains
unknown [4,5]. Studies that screened for the presence of a virus
expressed at the RNA level in human CLL, by using massive
sequencing technology, gave no evidence of a putative exogenous
viral candidate as a cause for this disease [6].
In order to gain insight into the role of endogenous retrovirus
in leukemogenesis, we studied np9 and gag gene expression of
HERV-K in Chronic Lymphocytic Leukemia (CLL) patients com-
pared to healthy donors.
The results revealed that 70% of CLL patients express np9 gene
at least 5 times higher than healthy donors, and 33% express gag
gene twice as high as normal donors. These ﬁndings suggest a
signiﬁcant relationship between CLL disease and HERV-K np9 (and
possibly gag) expression.
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2. Materials and methods
Peripheral blood samples were obtained from 25 patients with
a typical diagnosis of B cell-CLL (mean age: 64 years). The control
group consisted of 6 healthy volunteers. All patients were followed
at the Hospital Maciel from Montevideo and provided an informed
consent in accordance with national ethical regulations and the
Declaration of Helsinki.
The peripheral blood mononuclear cells (PBMC) were isolated
by centrifugation on Ficoll-Hypaque (GE Healthcare). RNA was
isolated from 1 to 5106 cells using the Trizol RNA Isolation
Protocol. To minimize genomic DNA contamination each RNA
sample was treated with DNA-free™ Kit (Ambion, USA). cDNA
synthesis was performed as described previously [7]. Negative
controls in which reverse transcriptase was omitted were per-
formed to conﬁrm the exclusion of residual genomic DNA
contamination.
For gene expression analyses of np9 and gag genes, we used the
KAPA SYBR FAST qPCR Kit Master Mix (2 ) Universal (Kapa
Biosystems) and a Corbett Rotor-Gene 6000. HERVs-K primer
sequences of np9 and gag were previously described [2,8]. The
cellular c-myc expression level in CLL patients was also assessed
with respect to healthy donors. The results of HERV-K and c-myc
expression were normalized to the level of glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) transcription using the fol-
lowing primers: forward: 50- GGTGCTGAGTATGTCGTGGA-30 and
reverse: 50-ATGCCAGTGAGCTTCCCGTT-30.
PCR cycling conditions for np9, c-myc and GAPDH ampliﬁcation
were: 3 min at 95 1C and 40 cycles at 95 1C for 3 s, 58 1C for 20 s
and 72 1C for 20 s. For HERV-K gag speciﬁc ampliﬁcation, cycling
conditions were: 95 1C for 10 min, 40 cycles at 95 1C for 15 s and
60 1C for 1 min. The threshold cycle value (Ct), computed for each
of these genes as the average of 2 determinations was used to
measure the amount of PCR product. The meanΔCt was calculated
by subtracting the mean Ct of duplicated np9 and gag measure-
ments from the mean Ct of duplicated GAPDH measurements. The
ΔΔCt values were calculated with the mean ΔCt of the 6 healthy
donors. The expression factor difference was calculated by the
formula 2ΔΔCt. Thus, the calculated relative expression provides
data on how much np9 and gag gene expression differs from that
found in healthy donors.
3. Results and discussion
In this study, the np9 and gagmRNA expressionwas established
for 25 patients with CLL (Fig. 1). We found that the transcriptional
activity of HERV-K np9 gene in CLL patients was higher than in
PBMCs from healthy donors. The results revealed that 18 out of 25
CLL patients (70% of CLL patients) express np9 transcripts ﬁve-fold
higher than in normal PBMCs (Fig. 1A). On the other hand when
we analyzed gag gene expression we noted that just 33% of CLL
patients expressed elevated gag levels (two-fold) compared to
healthy people (Fig. 1B). Both in np9 and gag analysis, a wide
variability of expression among patients was observed, with no
signiﬁcant difference between mutated and unmutated subgroups
(p¼0.65 and 0.09 respectively) (see Fig. 1).
A previous study regarding HERV-K gag transcriptional activity
[2] reported ﬁve to eight-fold higher gene expression in 3 B-CLL
patients analyzed. However, our study on a large number of B-CLL
patients showed that only 2 out of 25 patients exhibited elevated
gag expression (5-fold greater than healthy donors) (see Fig. 1B).
The overexpression of HERV-K Np9 protein has been observed
in a variety of leukemia cell lines and primary cultures of leukemia
cells [3]. It is known that the interaction of Np9 protein abrogates
the function of the promyelocytic leukemia zinc ﬁnger (PLZF) as a
transcriptional repressor of the c-myc proto-oncogene promoter,
resulting in the overproduction of this transcription factor and the
induction of cell proliferation [9]. Studies of Palacios et al. [10] in
CLL report that the proliferative behavior of a small CLL B-cells
subpopulation could be related to expression of c-myc oncogene.
Unfortunately our studies on c-myc gene expression levels in CLL
patients with high and low np9 mRNA expressions showed no
signiﬁcant differences (p¼0.19) in the expression of c-myc
between these groups, nor with normal PBMCs (Fig. 2). The
differences in these results could be explained by the distinct
CLL subpopulations analyzed in each work. Other plausible expla-
nation is that np9 mRNA might not be translated or alternatively,
that over expression of c-myc through a putative Np9 PLZF path-
way may be transient [9].
To our knowledge, this is the ﬁrst study of HERV-K np9 mRNA
expression in B cell-CLL showing that this molecule is over-
expressed in the peripheral blood of CLL patients compared with
healthy donors. More studies are needed to evaluate the potential
impact of np9 expression on CLL and its role in the regulation of
signaling pathways involved in carcinogenesis.
Fig. 1. np9 and gag mRNA relative expression levels in CLL patients with mutated
and unmutated proﬁle in their immunoglobulin Vh genes. (A) Relative expression
of HERV-K np9 gene with respect to healthy donors. The dotted line represents the
maximum value of np9 expression from healthy donors as a negative calibrator.
(B) Relative expression of HERV-K gag gene with respect to healthy donors. The
dotted line represents the maximum value of gag expression from healthy donors
as a negative calibrator. The vertical error bars represent the maximum value of
each CLL patient's sample measured by duplicated.
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